Renal Sympathetic Denervation: Hibernation or Resurrection?
The most current versions of renal sympathetic denervation have been invented as minimally invasive approaches for the management of drug-resistant hypertension. The anatomy, physiology and pathophysiology of renal sympathetic innervation provide a strong background supporting an important role of the renal nerves in the regulation of blood pressure (BP) and volume. In addition, historical data with surgical sympathectomy and experimental data with surgical renal denervation indicate a beneficial effect on BP levels. Early clinical studies with transcatheter radiofrequency ablation demonstrated impressive BP reduction, accompanied by beneficial effects in target organ damage and other disease conditions characterized by sympathetic overactivity. However, the failure of the SYMPLICITY 3 trial to meet its primary efficacy end point raised a lot of concerns and put the field of renal denervation into hibernation. This review aims to translate basic research into clinical practice by presenting the anatomical and physiological basis for renal sympathetic denervation, critically discussing the past and present knowledge in this field, where we stand now, and also speculating about the future of the intervention and potential directions for research.
Veteran Affairs Medical Center and Georgetown University, Washington, D.C., USA.
Vasilios
V
Papademetriou
Michael
M
Doumas
Costas
C
Tsioufis
D001794:Blood Pressure / Q000502:physiology; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D007668:Kidney / Q000294:innervation*; D059032:Learning Curve; D016032:Randomized Controlled Trials as Topic; D012077:Renal Artery / Q000294:innervation; D013562:Sympathectomy / Q000379:methods*; D013564:Sympathetic Nervous System / Q000033:anatomy & histology / Q000502:physiology; D014665:Vasodilator Agents / Q000627:therapeutic use
D014665:Vasodilator Agents